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The adhesion of human T lymphoblasts o ICAM-l-expressing normal dermal fibroblasts has been assessed as a sensitive model system for the 
analysis of the interaction of the leucocyte integrin LFA-I with its counter-receptor ICAM-I. Using this model system, the effects of factors known 
to regulate the activity of LFA-I have been quantitated: temperature; concentration of divalent cations; and exposure to phorbol esters. We show 
here that under the appropriate assay conditions, this model system represents a useful and simple alternative to the detection of leucocyte binding 
to purified ICAM-I and also has the additional advantage of permitting more sensitive quantification than is possible using the homotypic adhesion 
assay. 
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I. INTRODUCTION 
The LFA-I (CDI Ia/CDI8) molecule is a member of 
the leucocyte integrin family of adhesion receptors [1- 
6]. The expression of this adhesion receptor, which is 
restricted to white blood cells, is required for many 
leucocyte functions including T cell-mediated killing. 
T-helper and B lymphocyte responses, natural killing, 
antibody-dependent cellular cytotoxicity mediated by 
monocytes and granulocytes, and adherence of leuco- 
cytes to endothelial and epithelial cells and to fi- 
broblasts. These leucocyte flmctions are known to re- 
quire an adhesion step which is mediated by the interac- 
tion of LEA-I molecules expressed on leucocytes with 
counter-receptor ligand molecules expressed on 
target cells. 1CAM-I, the principal igand for LFA-I, 
was identified using as a model system, formation of 
intercellular homotypic aggregates induced after treat- 
ment of several ymphoid and myeloid cell lines with 
phorbol esters [6-8]. Monoclonal antibodies (mAb) spe- 
cific for ICAM-I have been selected by testing for abil- 
ity to int,!bit such LFA-l-dependent aggregates [9]. 
The fact that circulating and freshly isolated resting 
leucocytes express ignificant levels of both LFA-1 and 
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ICAM-I but do not aggregate strongly suggests the 
existence of mechanisms that regulate the interaction of 
LFA-I with ICAM-1. Although these mechanisms are 
not yet fully understood, it is known that they are de- 
pendent on temperature and metabolic energy, and re- 
quire the presence of divalent cations, particularly Mg =* 
[8,10-I 1]. Dependence on all these factors demonstrates 
that the LFA-I/ICAM-l-mediated cellular adhesion is 
an active process that requires more than the mere pres- 
ence of receptor and counter-receptor molecules on op- 
posing cell membranes [10,I 2,13]. Moreover, this regu- 
latory effect is mediated via LFA-I with ICAM-1 mole- 
cules seemingly being constitutively avid for LFA-1 
[4,5,10, !1]. The transition of LFA-1 into an active form 
which readily binds to ICAM-1 can be induced by intra- 
cellular signals generated through a number of leuco- 
cyte surface molecules including TcR/CD3 [12], CD2 
[12,14], CD43, CD44. CDI4 and MHC class II (for 
review see [I 5]). As phorbol esters are potent activators 
of protein kinase C, their LFA-I activating effect can 
also be explained by the involvement of an intracellular 
signalling mechanism. 
In order to characterize the mechanisms involved in 
the activation of LFA-I, sensitive quantification of  the 
LFA-I/ICAM-I binding is required. So far, the two 
most frequently used model systems for studying this 
interaction have been the induction of leucocyte homo- 
typic aggregation [8,16-18] and binding of leucocytes to 
purified ICAM-I [10-12]. In this paper we have charac- 
terized the adhesion of human T lymphoblasts omono- 
layers of ICAM- l-expressing fibroblasts under different 
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exper imenta l  cond i t iom and descr ibe this technique as 
a highly useful model  system for the analysis o f in t race l -  
lular as well as extracel lu lar  factors affecting the act iva- 
t ion o f  LFA-1  molecules result ing in enhanced interac- 
t ion wi th  ICAM- I .  
2. MATERIALS  AND METHODS 
2. I. Reagents 
MgCI.,. CaCI, and ethyleneglycol-bis-~-aminoethyl ether) 
N.N,N',N'-tetraaeetic acid (EGTA) were obtained from Fisons 
(Loughborough, UK): mCr (10-35 mCi/ml) was from Amersham In- 
ternational; (N-[2-hydroxyethyl]-piperazine-N'-[2-ethanesultbnic 
acid]) (HEPES). phorbol-12.13-dibutyrate (PdBu). cytochalasin D, 
and fluorescein isothiocynate (FITC)-goat anti-mouse lgG were from 
Sigma (UK). All tissue culture reagents were obtained from Gibco 
(UK) and all plasticware from Becton Dickinson (UK). 
2.2. Monoclonal antobodies 
The monoclonal antibodies 15.2 (anti-lCAM-l, CD54), 38 (anti- 
LFA- I, CD 11 a), 44 (anti-CR3, CD I I b) and 3.9 (anti-p 150.95. CD 11 c) 
have been described elsewhere [I9-22]. The anti-ICAM-I mAb 8.4A2 
is a generous gift from Dr. Dorian Haskard (London, UK). The 
following monoclonal antibodies were generous gifts: PIE6 (anti- 
VLA-2. CD49b), PIB5 (anti-VLA-3. CD49c), PID6 (anti-VLA-5, 
CD49e) and P4CI0 (anti-VLA ,St, CD29) (Dr. Elizabeth Wayner, 
Seattle, USA): HP2/I (anti-VLA-4, CD49d) (Dr. Francisco Sanchez- 
Madrid. Madrid, Spain): GT2 (anti-LFA-2. CD2) (Dr. Alain Bernard. 
Villejuif. France): 4B2 (anti VCAM-I) (Dr. David Simmons. Oxford, 
UK): UCHTI (anti-CD3) (Dr. Peter Beverly. London, UK); TS2/9 
(anti-LFA-3, CD58) (Dr. Timothy Springer. Boston. USA). The null 
mAb MOPC 21 (generous gift from Dr. Gordon Ross) has been used 
as a control in all experiments. 
2.3. Flow c.r/ome/ric aJ~alysis 
Cells (5 x 10S/test) were pelleted in flexible 96-well microtitre plates, 
resuspended in 50,ul ofmAb tissue culture supernatant and incubated 
for 30 min on ice. After three washes with RPMI-1640 medium, cells 
were resuspended in 50 ,ul of FITC-goat anti-mouse IgG (Cappel, 
1:400 in medium) and incubated for 30 rain on ice. Finally, ceils were 
washed twice with RPMI-1640. resuspended in 300 pl of RPMI-1640 
and analyzed using a Becton Dickinson FACScan flow cytometer. 
2.4. Cells and cell culture 
Human foreskin dermal fibroblasts, obtained from the ICRF Cell 
Production Department and cultured in MEM medium supplemented 
with 10% FCS. were used between passages 6 and 10. Peripheral blood 
mononuclear cells (PBMC) were obtained from freshly-drawn hepa. 
rinised blood by centrifugation over Ficoll/Hypaque (Pharmacia, 
Uppsala, Sweden). Human T lymphoblasts were prepared by stimu- 
lating PBMC with 5 /.tg of phytohaemagglutinin/ml and 50 nM 
phorbol-12.13-dibutyrate (PdBu) for 48 h in P, PMI-1640 medium 
supplemented with 10% FCS. and then culturing for up to 14 days in 
RPMI-1640 medium containing 10% FCS and 5% culture supernatant 
from the IL-2-producing cell line MLA [23]. 
2.5. Binding assay 
Human fibroblasts were transferred from tissue culture flasks into 
96-well plates and grown to confluence. Culture supernatants were 
tl~en discarded and fibroblasts were fixed with 2% formaldehyde in 
PBS (150/al/well) for I h at room temperature. Using this protocol. 
the fibroblasts remained firmly adherent to the wells during all the 
described assay conditions. Wells were then washed six times lbr 10 
rain with 200/al of PBS without Ca :~ or Mg :+. At this stage, plates 
could be stored at 4°C for several days. 5 x 10 7 T lymphoblasts were 
labelled with 200 ,uCi s~Ct'O4-" in I ml of RPMI/2% FCS for 90 rain 
at 37°C. washed and incubated inRPMI/10% FCS for 40 min at 37°C, 
Finally. T lymphoblasts were washed three times in assay buffer con. 
sisting of 20 mM HEPES, 140 mM NaCI, 2 mg/ml glucose, pH 7.4. 
and resuspended in this buffer at 4 x 106 eells/ml. Fifty/tl of assay 
buffer containing the appropriate concentrations of reagents (mAbs. 
divalent cations, PdBu, cytochalasin D) and 50/..d of T lymphoblasts 
were added to each well on ice. Plates were then centrifuged at 30 × 
g for I rain in order to gently pellet the T cells onto the fibroblast 
monolayer, and incubated at the temperature r quired (4°C or 37°C) 
for 35 rain. After incubation, wells were washed three times with 200 
,ul of warm RPMI-1640 (37°C) and finally the T lymphoblasts were 
lysed with 40/~l of 1% Triton X-100 in water for determination f
incorporated radioactivity. All binding assays were carded out in 
triplicate and the standard errors were always less than 10%. 
3. RESULTS AND DISCUSSION 
The model  systems most  general ly used to analyze the 
act ivat ion o f  LFA- I  have been the homotyp ic  leucocyte 
aggregat ion assay and leucocyte b inding to purif ied 
ICAM-1 .  A l though determinat ion  o f  leucocyte b ind ing 
to immobi l i zed  ICAM-1  is the best def ined system in 
molecu lar  terms, pur i f icat ion of  ICAM- I  is a tedious, 
expensive and t ime consuming  procedure  which in- 
volves growing large amounts  o f  ICAM- l -express ing  
cells and  yields only smal l  amounts  o f  pur i f ied ICAM- I .  
On the other  hand,  the induct ion o f  leucocyte homo-  
typic aggregates is a very simple qual i tat ive assay but  
has the drawback  o f  be ing diff icult to precisely quan-  
titate. These diff iculties arise from the subject iv i ty im- 
plicit in the count ing o f  large numbers  o f  aggregates and  
free cells. In this paper  the adhes ion  o f  human T lym- 
phoblasts  to mono layers  o f  ICAM- l -express ing  normal  
skin f ibroblasts  has been used as a simple a l ternat ive 
model  system giving h ighly  specific and sensit ive quan-  
t i f ication o f  the interact ion o f  LFA-1 with ICAM- I  and  
al lowing analys is  of  the requi rements  for the act ivat ion 
Table I 
Expression of adhesion receptors and counter-receptors n human T 
lymphoblasts and skin fibroblasts 
mAb T lymphoblasts Fibroblasts 
- 2.97 (2.1) 4.93 (3.5) 
38 (CD1 la. LFA-I) 94.79 (100.0) ND 
44 (CD1 lb, CR3) 3.85 (4.2) ND 
3.9 (CDI lc, p150-95) 3.94 (6.9) ND 
15.2 (CD54, ICAM-1) 15.06 (84.1) 109.64 (99.9) 
UCHTI (CD3) 50.58 (97.5) ND 
TS2/9 (CD58, LFA-3) 17.97 (93.4) 33.3 (99.7) 
GT2 (CD2. LFA-2) 15.03 (95.0) ND 
PIE6 (CD49b, VLA-2) 7.61 (37.0) 71.34 (100.0) 
PIB5 (CD49c. VLA-3) 8.05 (49.3) 53.69 (100.0) 
HP2/I (CD49d, VLA,4) 32.34 (97.2) 45.19 (100.0) 
PID6 (CD49e, VLA-5) 13.16 (77.4) 136.88 (100.0) 
P4CI0 (CD29, VLA fit) 36.60 (99.7) 280.02 (100.0) 
4132 (VCAM-I) ND 6.15 (11.4) 
W6/32 (HLA Class I) ND 240.77 (100.0) 
Binding of mAbs was assayed by flow cytometry as described in 
Materials and Methods. Values represent me~m peak fluorescence 
(MFI) and numbers in parentheses represent percentage of positive 
cells. ND, not determined. 
285 
Volume 292, number 1,2 
of LFA-I molecules which results in binding to ICAM- 
1. Other studies have already described this adhesion 
between human or murine T cells and fibroblasts but 
none of these studies have characterized the LFA-I/ 
ICAM-I interaction and focussed on the factors that 
control LFA-1 activity [24,25]. 
The expression of adhesion receptors and counter- 
receptors on both the human T lymphoblasts and fibro- 
blasts used in this work is shown in Table I. It is inter- 
esting that these T lymphoblasts express ignificant lev- 
els of both LFA-I and ICAM-I but do not spontane- 
ously form homotypic intercellular clusters after two 
weeks in culture. This fact indicates that LFA-I is in an 
inactive form and has to be activated in order to readily 
interact with ICAM-1. In addition, these T lympho- 
blasts also express the adhesion pair CD2/CD58 and 
several members of the B~ integrin family of VLA recep- 
tors specific for extracellular matrix proteins. On the 
other hand, the dermal fibroblasts express ICAM-I, 
VLA and LFA-3 (CD58) but show very little expression 
ofVCAM-I,  a ligand for VLA-4. 
In order to restrict effects to the activity of LFA-I on 
T cells it was decided to fix the ICAM-l-expressing 
fibroblasts prior to the addition ofT iymphoblasts. This 
fixation step adds the additional advantage of permit- 
ting the study of LFA-l-dependent T cell adhesion 
under conditions such as the absence of divalent cations 
or low temperature that would lead to the detachment 
FEBS LETrERS November 1991 
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of many fibroblasts from plastic, with the subsequent 
loss of sensitivity and accuracy of the assay. Since for- 
maldehyde, as well as many other cross-linking fixa- 
tives, is known to alter or even destroy some epitopes 
on a number of cell surface antigens [26] the effect of the 
fixation protocol was tested on the expression of two 
different functional epitopes expressed on ICAM-1 mo- 
lecules on fibroblasts. The expression of ICAM-I epito- 
pes recognized by mAb 15.2 and 8.4A2 remained unaf- 
fected after fixation (Fig. 1) suggesting that the confor- 
mation of the ICAM-l-rnolecules on fibroblasts is pre- 
served after a rigorous fixation protocol and that func- 
tional activity might also be unaffected. Fig. 2 shows 
that this is indeed the case since T lymphoblast adhesion 
to the ICAM-l-expressing fibroblasts was achieved 
when the binding assay was done in RPMI-1640 at 
37°C in the presence of phorbol ester PdBu (50 nM). 
The LFA-i/ICAM-I specificity of this interaction is 
demonstrated bythe inhibitory effect of both anti-LFA- 
1 or anti-ICAM-1 mAb as compared to the control 
mAb MOPC 21. In a previous report [24], Abraham et 
al. found that the spontaneous binding of T lympho- 
blasts to monolayers of human fibroblasts in normal 
medium and in the absence of any stimulation was al- 
most completely lost after fixation of the fibroblasts 
with paraformaldehyde but that such adhesion seemed 
to be LFA-I/ICAM-I independent. This finding is con- 
sistent with our results ince the percentage ofspontane- 
L.  
E 
oJ t J  
rnAb 15.2 
NON FIXED FIBROBLASTS 
mAb 8.4A2 
.i il 
- it 
IB  ~ '  ' '1'~ | . . . .  I c~2 . . . . . . .  ' 13 . . . . . . .  
i:: 
i !  
: ii 
t 
mAb 15,2 
FIXED FIBROBLASTS 
i i i  
mAb 8,4A2 
' . . . .  L _ 
Fluorescence Intensity 
Fig, 1, Effect of formaldehyde fixation on ICAM-I expressed on human dermal fibroblasts. The expression of two functionally different epitopes 
detected by mAbs 15,2 ~nd 8,4A2 on ICAM-I remains unaffected af'ter fixation or the fibrobhlsts with 2% formaldehyde rot 1 I1, Staining with 
mAb MOPC 21 is also included as a negative control, 
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Fig. 2. Effect of phorbol ester treatment (50 nM) on the adhesion of 
T lymphoblasts to ICAM-l-expressing human dermal fibroblasts. The 
LFA-I/ICAM-I specificity of this adhesion is demonstrated bythe 
strong inhibitory effect of anti-LFA-I (mAb 38) or anti-ICAM-1 
(mAb 15.2) mAbs. The null mAb MOPC 21 was used as a control• All 
mAbs were used at 10 #g,/ml. The binding assay was carried out in 
RPMI-1640 at 37°C for 35 min. 
ous T lymphoblast binding to the fixed fibroblasts in the 
absence of  phorbol ester stimulation is low (Fig. 2), 
which clearly indicates a requirement for LFA-1 activa- 
tion. Also, very little binding o fT  lymphoblasts (always 
below 5%) could be observed at 4°C (data not shown) 
which is also in agreement with the known temperature 
dependence of LFA-I activation [12]. 
This adhesion model system was next applied to the 
analysis of the Mg 2÷ dependence of LFA-I activation. 
In the absence of  any divalent cation, PdBu did not 
induce T lymphoblast binding to the fixed fibroblasts, 
which is in accordance with the known Mg 2÷ require- 
ment for LFA-I / ICAM-1 interaction [8,10,11]. The per- 
centage of T lymphoblasts that bind to ICAM.I .ex- 
pressing fibroblasts increases with the concentration of 
Mg :÷ (Fig. 3). At a concentration of 1 mM Mg 2÷ appro- 
ximately 45% of T lymphoblasts adhere to the fi- 
broblasts and this adhesion is LFA-1/ ICAM-l -depend- 
ent as demonstrated by inhibition with anti-LFA-1 or 
anti- ICAM-I mAbs. It is worth noting that the normal 
60-  
55-  
~J LFA-1 
50-  [ ]  ICAM.1 
[ ]  LFA-I+ICAM-1 
45 
40 
Z 
0 
m 35 
ul 
~ 3o  
0 
o. 
~ 25  
. J  
N 20  
15 
10, 
5 -  
0 
0 0.2 1 
2*  
Mg concent ra t ion  ( raM)  
Fig. 3. Phorbol ester-induced a hesion of T lymphoblasts to ICAM- 
l-expressing fibroblasts is Mg:*-dependent. Concentrations of 
phorbol ester PdBu and mAbs are the same as in Fig. 2. The assay was 
done in assay buffer containing 20 mM HEPES. 140 mM NaCI, I mM 
EGTA, 2 mg/ml glucose and the indicated concentrations.of Mg:" at 
37°C lbr 35 min. 
extracellular concentration of  Mg :+ is in the range of  
1-2 raM, which suggests that the amount of  this cation 
required for LFA-1 activation is consistent with phy- 
siological evels. It is interesting that the percentage of  
inhibition of  T cell adhesion that can be obtained with 
anti-LFA-1 or anti- ICAM-I mAb in the presence of  
PdBu is greatly decreased when the concentration of  
Mg 2+ is higher than I mM. This finding suggests that 
at high concentrations of Mg -~+, phorbol esters preferen- 
tially activate other lymphocyte-fibroblast adhesion 
pathways. It seems unlikely that this effect of Mg 2+ and 
phorbol esters is mediated by the CD2/LFA-3 pair as 
this adhesion pathway is neither regulated by divalent 
cations nor by phorbol esters [27,28]. Another possibil- 
ity is that it is mediated by members of the fl~ integrin 
family since the activity of various fibronectin receptors 
has been reported to be regulated by divalent cations 
and phorbol esters [29-3 I]. 
Using this model system, the synergistic effect of Ca 2÷ 
on the activation of LFA-1 in the presence of  low con- 
centrations o f  Mg ~÷ (below 1 raM) and PdBu has been 
quantitated (Fig. 4). The results are in accordance with 
those described by other groups using as model systems 
the phorbol ester-induced homotypic aggregation of B 
and T lymphocytes or detection of B cell binding to 
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Fig. 4. Ca -'~ (! raM) has a potentiating effect on the PdBu-induced 
adhesion of T lymphoblasts o ICAM-l-e~;pressing fibroblasts. Con- 
centrations of PdBu and mAbs are the same as in Figs. 2 and 3. The 
assay was done in assay buffer containing 20 mM HEPES, 140 mM 
NaCI. 2 mg/ml glucose plus either EGTA (l raM) or Ca -'÷ (I raM) and 
the indicated concentrations of Mg > at 37°C for 35 rain. 
purified ICAM-I [8,11]. This synergistic effect of Ca 2÷ 
and Mg -'~" on phorbol ester-induced activation may ex- 
plain the strong potentiating effect of phorbol esters on 
LFA-I/ICAM-1 interaction when the assay is done in 
normal culture medium RPMI-1640 (where the concen- 
trations of Mg -'+ and Ca =+ are both 0.4 raM) (see Fig. 
2). Under these conditions, a large proportion of the 
binding of T lymphoblasts to the fibroblasts is LFA-I/ 
ICAM-I dependent. 
In summary, using the adhesion of human T lympho- 
blasts to monolayers of normal dermal ICAM-l-expres- 
sing fibroblasts as a model system for analysis of the 
LFA-I/ICAM-I interaction, we have been able to quan- 
titate all the previously known requirements for the 
activation of LFA-I molecules. The results show that 
the percentage of the adhesion o fT  lymphoblasts o the 
fibroblasts that is LFA-1/ICAM-dependent can be re- 
gulated by selecting the assay conditions, i.e. the con- 
centrations of Mg =" and Ca -'+ and presence or absence 
of phorbol esters. Also, under the appropriate condi- 
tions this model system could be applied to large-scale 
screening for mAbs specific for ICAM-1 or for LFA-1 
based on their ability to inhibit this interaction. Finally, 
this model system also permits an easy quantification of 
the relative importance of defined LFA-I or ICAM-1 
epitopes on this interaction simply by revealing the in- 
hibitory effect of mAbs directed to any such epitopes. 
Acknowledgements: This work has been supported by The Imperial 
Cancer Research Fund. C.C. is a recipient of a "'Plan de Formation 
de Personal Inves,igador'" Postdoctoral Fellowship from "Ministerio 
Espaflol de Edueaci6n y Ciencia". Carlos Cabaflas is a ICRF Visiting 
Research Fellow from Departamento deBioquimica y Biologia Mo- 
lecular. Facultad e Medicina. Universidad Complutense, 28040 Ma- 
drid. Spain. 
REFERENCES 
[I] Hogg, N. (t989) lmmunol. Today 4, l I l-114. 
[2] Kishimoto. T.K.. Larson, R. Corbi, A.L., Dustin. M.L., 8taun- 
ton, D.E. and Springer, T.A. (1989) Adv. lmmuno!. 46, 149-182. 
[3] Arnaout. M.A. (1990) Blood 75. 1037-1050. 
[4] Springer, T.A, (1990) Nature 346, 425-434. 
[5] Springer, T.A, (1990) Annu. Rev. Cell Biol. 6. 359402. 
[6] Springer. T.A., Dustin, M.L., Kishimoto, T.K. and Marlin. S.D. 
(1987) Annu. Rev. Immunol. 5. 223-252. 
[7] Patarroyo, M., Jondal, M,. Gordon, J. and Klein, E. (1983) Cell. 
lmmunol. 81,373-383. 
[8] Rothlein. R. and Springer, T.A. (1986) J. Exp. Med. 163, 1132- 
i 149. 
[9] Rothlein, R., Dustin, M.L., Marlin, S.D. and Springer, T.A. 
(1986) J. Immunol. 137, 1270-1274. 
[10] Marlin. S. and Springer, T.A. (1987) Cell 51,813-819. 
[1 l] Makgoba, M.W., Sanders. M.E., GintherLuce. G.E., Dustin. 
M.L.. Springer, T.A., Clark, E.A.. Mannoni. P. and Shaw. S. 
(1988) Nature 331, 86-88, 
[12] Dustin, M.L. and Springer, T.A. (1989) Nature 341,619-624. 
[13] Figdor, C.G., Van Kooyk, Y. and Keizer, G.D. (1990) Immunol. 
Today 11. 277-280. 
[14] Van Kooyk, Y., Kemenade. W., Weder, P., Kuijpers, T.W. and 
Figdor, C.G. (1989) Nature 342, 811-813. 
[15] Hogg, N. (1991)Chem. lmmunol. 50, 1-12. 
[I 6] Patarroyo. M.. Jondal, M,, Gordon, J. and Klein, E. (1983) Cell. 
lmmunol. 81, 373-383. 
[I 7] Cabaflas, C., Sanchez-Madrid. F . Aller, P,, Yague. E. an~ Ber- 
nabeu. C. (1990) Eur. J. Biochom. 191,599-604. 
[18] Cabaflas, C.. Lastres. P., BeUon, T,, Aller, P.. Figdor, C.G., 
Corbi, A. and Bernabeu, C. (1991) Biochim. Biophys. Aeta 1092, 
165-168. 
[I 9] Dransfield. i , Cabafias. C.. Barret, J. and Hogg, N. ( 199 I) (Sub- 
mitted). 
[20] Dransfield, I. and Hogg, N. (1989) EMBO J. 8, 3759-3765. 
[21] Malhotra, V.. Hogg, N. and Sims, R.B. (1986) Eur. J. lmmunol. 
16, I117-1123. 
[22] Hogg, N., Takacs, L. Palmer, D.G., Sevendran, Y. and Allen. C. 
(1986) Eur. J. i'mmunol. 16, 240-248, 
[23] Cantrcll. D.A., Davies. A.A. and Crumpton, M.J. (1985) Proc. 
Natl. Acad. Sci. USA 82, 8158-8162. 
[24] Abraham, D., Inee. T., Muir, H. and Olsen, I. (1989) J, Invest. 
Dermatol. 93, 335-340. 
[25] Jack, A.S. and Chapman, K.J. (1991) J. Pathot. 164, 151-158. 
[26] Wilson, E.B., Sun, S. Ozturk, M. and Wands. J.R. (1991) J. 
lmmunol. Methods 139, 55-64. 
[27] Makgoba, M.W., Sanders. M.E. and Shaw, S. (1989) Immunol. 
Today 10, 417-422, 
[28] Moingeon, P.E.. Lucich. J.L., Stebbins. C.C., Recny, M.A., Wall- 
ner, B.P., Koyasu, S. and Reinherz, E.L. (1991) Eur. J. Immunol. 
21,605-610. 
[29] Danilov, Y.N. and Juliano, R.L. (1989) J. Cell Biol. 108, 1925- 
1933. 
[30] Homier. M.E., Elices, M., Chan. B.M.C., Zetter, B., Malsuura, 
N. and Takada, Y. (1990) Cell Diff. Dev. 32, 229-238. 
[31] Elites, MJ.. Urry. L.A. and Homier, M. (1991)J. Cell Biol. 112, 
169-181, 
288 
